Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods,
together with associated computational tools and the growing availability of public data …

Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …

Colorectal cancer (CRC) is among the most common malignancies with limited treatments
other than surgery. The tumor microenvironment (TME) profiling enables the discovery of …

The consensus molecular subtype (CMS) classification of colorectal cancer is based on bulk
transcriptomics. The underlying epithelial cell diversity remains unclear. We analyzed …

Long noncoding RNAs (lncRNAs) are recently implicated in modifying immunology in
colorectal cancer (CRC). Nevertheless, the clinical significance of immune-related lncRNAs …

As the third most common malignancy and the second most deadly cancer, colorectal
cancer (CRC) induces estimated 1.9 million incidence cases and 0.9 million deaths …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd)
tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors …

Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …